Compare ASB & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ASB | EWTX |
|---|---|---|
| Founded | 1861 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 4.8B |
| IPO Year | 2014 | 2021 |
| Metric | ASB | EWTX |
|---|---|---|
| Price | $29.61 | $45.48 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 6 |
| Target Price | $29.75 | ★ $39.00 |
| AVG Volume (30 Days) | ★ 1.7M | 1.0M |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.45% | N/A |
| EPS Growth | ★ 284.72 | N/A |
| EPS | ★ 1.33 | N/A |
| Revenue | ★ $1,102,756,000.00 | N/A |
| Revenue This Year | $21.24 | N/A |
| Revenue Next Year | $8.86 | N/A |
| P/E Ratio | $22.47 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $23.86 | $14.25 |
| 52 Week High | $32.46 | $48.51 |
| Indicator | ASB | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 38.27 | 58.11 |
| Support Level | $27.03 | $41.31 |
| Resistance Level | $29.96 | $48.40 |
| Average True Range (ATR) | 0.59 | 2.00 |
| MACD | -0.09 | 0.26 |
| Stochastic Oscillator | 22.49 | 66.26 |
Associated Banc-Corp is a bank holding company based in the United States of America. The company, through its subsidiaries, provides a broad array of banking and non-banking products and services to individuals and businesses. The group operates in three reportable segments: Corporate and Commercial Specialty; Community, Consumer, and Business; and Risk Management and Shared Services. The majority of its revenue is derived from the Corporate and Commercial Specialty segment, which serves a wide range of customers, including larger businesses, developers, not-for-profits, municipalities, and financial institutions by providing lending and deposit solutions as well as support to deliver, fund, and manage such banking solutions.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.